Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD2 | Q15562 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23363754 | 1.00 | TEAD2 (0.34) | TEAD2PARP1KDM1A | |
| SCHEMBL29938019 | 0.80 | KDM1A (0.32) | TEAD2PARP1KDM1A | |
| SCHEMBL24750257 | 0.80 | KDM1A (0.32) | TEAD2PARP1KDM1A | |
| SCHEMBL29149542 | 0.80 | KDM1A (0.32) | TEAD2PARP1KDM1A | |
| SCHEMBL23363757 | 0.78 | TEAD2 (0.35) | TEAD2PARP1 | |
| SCHEMBL23363909 | 0.78 | TEAD2 (0.33) | TEAD2 | |
| SCHEMBL23363913 | 0.78 | TEAD2 (0.33) | TEAD2 | |
| SCHEMBL23363755 | 0.78 | TEAD2 (0.35) | TEAD2PARP1 | |
| SCHEMBL23363891 | 0.78 | TEAD2 (0.35) | TEAD2PARP1 | |
| SCHEMBL23364210 | 0.78 | TEAD2 (0.35) | TEAD2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058435-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20220281819-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114728905-A | Therapeutic compounds and methods of use | 基因泰克公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021097110-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021097110-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281819-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, NQO1, PCSK9 | TEAD2 22/4885PARP1 1133/4885KDM1A 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.